Our data suggest that TGFβ and ET‐1 blockade might represent a potential future strategy to treat muscle fibrosis, particularly in the pharyngeal muscles of patients suffering from OPMD and achalasia but also in other muscle pathologies involving fibrosis. This evidence concerns the gene TGFB1 and oculopharyngeal muscular dystrophy.